Trial Profile
A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Zilucoplan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Ra Pharmaceuticals
- 12 Apr 2022 Status changed from completed to discontinued.
- 10 Jan 2022 Status changed from active, no longer recruiting to completed.
- 05 Nov 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.